ReviewDermatologie (Heidelberg, Germany)2026
[Biologics and infections: treat and prevent].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although biologics used for systemic therapy of dermatological conditions are generally well tolerated, infection complications can still occur depending on the specific substance. Important measures to increase patient adherence to therapy, therefore, include providing appropriate information about the possible occurrence of infections, their prevention, and treatment. For example, in the case of recurrent Candida infections of the skin and mucous membranes under treatment with interleukin (IL)-17 blockers, fluconazole can be administered once a week as recurrence prophylaxis. In cases of increased risk of herpes zoster under systemic therapy with rituximab, mogamulizumab, or anifrolumab, vaccination with the adjuvanted herpes zoster subunit (HZ/su) attenuated vaccine is recommended. This article on infectious complications under systemic therapy with biologics summarizes possible infection prevention measures and treatment strategies.
Indexed as
Identifiers
42228091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.